Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...

Generic drugs had a "stable" performance in the second quarter, with global revenue down about 2% in local currency.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with ...

Tremors, stiffness, and slowed movement are classic signs of Parkinson's disease. Learn more about the signs and symptoms of ...

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

The second international consensus conference on the scapula was held in Lexington Kentucky. The purpose of the conference was to update, present and discuss the accumulated knowledge regarding ...

Medically reviewed by Nicholas R. Metrus, MD Tardive dyskinesia and dystonia are both neurological disorders that can affect ...